Estimation of the efficiency of using interferon inducer in children with Epstein-Barr viral infection

The aim of the research. To evaluate the effectiveness of synthetic low-molecular interferon inducers in children with Epstein-Barr viral infection. Material and methods. The study included 68 children aged 7 to 17 years with primary Epstein-Barr viral infection: 38 children in the main group received basic therapy against the primary form of Epstein-Barr viral infection in age-specific dosages in combination with a synthetic low-molecular interferon inducer; 30 children of the control group received the conventional basic therapy with age-specific dosages. Results. It has been established that clinical manifestation of Epstein-Barr viral infection is based on immunopathological inflammation mediated by the factors of cellular immunity. As a result of the therapy, 78.95 % of children in the main group had a normal rate of functional recovery of the liver. In the control group, however, the recovery was delayed in 60.00 % of children: rapid recovery was only noted in the main group. Administration of synthetic lowmolecular weight interferon inducers in addition to basic symptomatic therapy facilitated the reduction of intoxication symptoms duration by 4.7±1.9 days (p < 0.05) and the duration of the icteric period by 5.3±0.9 days (p < 0.05), as well as 5.1±1.3 days earlier normalisation of liver size (p < 0.05). Conclusion. Thus, the use of synthetic low molecular weight interferon inducers in combination with basic therapy against the primary form of Epstein-Barr viral infection in children contributes to a faster restoration of the functional state of the liver. The conducted clinical and biochemical studies indicate high efficiency of synthetic low molecular weight interferon inducers in the complex therapy of Epstein-Barr viral infection in children.

Assessment of the antiproliferative effect of antiviral drugs

Key words: interferon inducers, interferons, bone marrow cell proliferation, Oscillococcinum, Kagocel, Reaferon, Ingavirin

Comorbid patient with acute respiratory viral infections. Features of therapy and prevention

The article presents the definition of comorbid pathology, discusses issues of prevalence, features of management, assessment of the forecast. The characteristic of complications of acute respiratory viral infections, risk groups of complications, the effect of comorbidity on the course of acute respiratory viral infections, the risk of complications and death, signs of disease progression are given, indications for hospitalization are defined. The treatment of ARVI, etiotropic therapy, interferons, interferon inducers are considered. The methods of prevention of influenza and other acute respiratory viral infections are presented: specific and nonspecific prevention.

The use of innovative domestic interferon inducer for the prevention and treatment of acute respiratory viral infections in children

The article presents data on the place of the modern endogenous interferon inducers in the treatment and prevention of influenza and ARVI in children and the mechanisms of action. The focus is on the domestic antiviral innovation Kagocel which demonstrated high clinical efficacy and safety in a number of multi-center, blind, placebo-controlled studies of the treatment and prevention of ARVI/flu in children over 2 years old.